US › Healthcare

LeonaBio, Inc. (LONA)

US · Healthcare · Biotechnology

$7.66+2.54%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-32.9M

Profit YoY

-260.4%

EPS

$-1.73

EPS estimate

$-2.50

EPS came in at -1.73 against a street estimate of -2.50 — a beat of 30.8%.

Key statistics

Market cap

$66.3M

Forward P/E

0.0

P/B

1.34

Book value

$5.25

EPS (TTM)

$-23.95

52-week high

$14.21

52-week low

$3.53

50-day MA

$8.55

200-day MA

$7.05

Beta

2.02

Analyst view

with an average price target of $18.00.

Shareholding

Insiders

4.51%

Institutions

70.18%

Largest institutional holders

Fund	Stake
Perceptive Advisors LLC	19.79%
Kalehua Capital Management LLC	8.38%
ADAR1 Capital Management LLC	7.74%
COMMODORE CAPITAL LP	4.94%
TCG Crossover Management, LLC	4.94%
NEA Management Company, LLC	4.94%
Spruce Street Capital LP	4.19%
Vanguard Capital Management, LLC	2.07%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for LeonaBio, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.